#Sweden #Stockholm #BioArctic #Philip Scheltens #Linda Nilsson

Upcoming Board Election at BioArctic AB

BioArctic AB, a Swedish biopharmaceutical company dedicated to innovative treatments for neurodegenerative diseases, is preparing for its Annual General Meeting scheduled for May 28, 2026. The Nomination Committee has officially announced proposals concerning the composition of its Board of Directors, consisting of eight members.

Nomination Committee Proposals

The Nomination Committee has suggested re-electing six current Board members: Eugen Steiner, Cecilia Edström, Anna-Lena Engwall, Lars Lannfelt, Lotta Ljungqvist, and Mikael Smedeby. Additionally, it has proposed the election of two new members, Philip Scheltens and Linda Nilsson, expanding the body's expertise and perspectives. This decision aligns with the company’s growth and strategic vision as it progresses in its innovations.

Eugen Steiner is recommended to continue as Chairperson of the Board, fortifying continuity in leadership. In a shift of representation, board member Pär Gellerfors has opted not to seek re-election, paving the way for his daughter, Linda Nilsson, to assume the role, thus maintaining family representation in the governance structures.

Profiles of New Board Members

Philip Scheltens

Philip Scheltens is a distinguished figure in Alzheimer's research and treatment, with a career dedicated to advancing methodologies and solutions in cognitive neurology. His extensive background includes founding the Alzheimer Center at Amsterdam University Medical Centers and leading numerous high-stake clinical trials. As a senior figure at EQT Life Sciences, he oversees the Dementia Fund and contributes to pivotal research that addresses dementia issues.

His repute as a knowledgeable voice in the Alzheimer community makes him a valuable addition to BioArctic's Board. His independence from the company's management and major shareholders underlines his capacity to bring objective insights to the table.

Linda Nilsson

Linda Nilsson brings with her over 20 years of dynamic experience from HM, where she has disrupted and established success in product operations. In her current role, she leads a team of approximately 400 and innovates strategic frameworks that directly impact production efficiency and market responsiveness. Her prior responsibilities as Global Managing Director for Womenswear demonstrate her acute understanding of overseeing large-scale operations and driving revenue.

While Linda is independent in relation to the company, her ties to major shareholders signify a balance between corporate governance and stakeholder interests. Her business acumen will undoubtedly contribute to the Board's effort in steering BioArctic towards further successes in the biopharmaceutical landscape.

Context and Rationale

The Nomination Committee is a crucial component of the governance at BioArctic, reflecting shareholder interests in the company's direction. The formation adheres to the principles set by the Annual General Meeting of 2024, with members representing significant portions of ownership in the company. This process underlines the commitment to transparency and shareholder engagement.

Their full recommendations, including more detailed information on each proposed member, will be available on BioArctic's website in preparation for the 2026 Annual General Meeting.

As BioArctic continues its pioneering approach to therapies for Alzheimer’s and other neurodegenerative conditions, the new Board composition aims to fortify its leadership with expert insights, operational excellence, and strategic foresight.